ciprofloxacin has been researched along with Benign Neoplasms in 98 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of this study was to test the efficacy of oral ciprofloxacin in the treatment of lower risk febrile neutropenia (LRFN) in children treated for malignant diseases." | 9.09 | Oral ciprofloxacin in the management of children with cancer with lower risk febrile neutropenia. ( Armada, A; Cáceres, E; Casimir, L; Debbag, R; Fernández, C; Firpo, V; Latella, A; Paganini, H; Rodriguez-Brieshcke, T; Zubizarreta, P, 2001) |
| "Outpatient therapy with either oral ciprofloxacin or intravenous ceftriaxone for fever and neutropenia is effective and safe in pediatric patients with solid tumors and stage I/II non-Hodgkin lymphoma (low-risk patients)." | 9.09 | Oral ciprofloxacin vs. intravenous ceftriaxone administered in an outpatient setting for fever and neutropenia in low-risk pediatric oncology patients: randomized prospective trial. ( Campos, MC; Dantas, LS; Ginani, VC; Petrilli, AS; Seber, A; Tanaka, C, 2000) |
| " The use of monotherapy with intravenous ciprofloxacin (200 to 300 mg every 12 h) was evaluated against combined therapy with piperacillin plus amikacin in febrile granulocytopenic patients with solid tumor or lymphoma." | 9.07 | Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors. The European Organization for Research on Treatment of Cancer ( Calandra, T; Gaya, H; Glauser, M; Klastersky, J; Meunier, F; Viscoli, C; Zinner, SH, 1991) |
| "To compare the effectiveness and toxicity of ciprofloxacin vs an aminoglycoside, both in combination with a beta-lactam, for the treatment of febrile neutropenia in the inpatient setting." | 8.82 | Ciprofloxacin vs an aminoglycoside in combination with a beta-lactam for the treatment of febrile neutropenia: a meta-analysis of randomized controlled trials. ( Bliziotis, IA; Christodoulou, C; Chrysanthopoulou, S; Falagas, ME; Kasiakou, SK; Michalopoulos, A; Samonis, G, 2005) |
| "The objective of this investigation was to assess retrospectively the safety and the efficacy of oral ciprofloxacin plus cefuroxime axetil compared to the combination of oral ciprofloxacin plus amoxicillin/clavulanate, as initial outpatient treatment, in low-risk cancer patients with fever and neutropenia." | 7.74 | Comparison of two oral regimens for the outpatient treatment of low-risk cancer patients with chemotherapy-induced neutropenia and fever: ciprofloxacin plus cefuroxime axetil versus ciprofloxacin plus amoxicillin/clavulanate. ( Karabelis, A; Kordossis, T; Kosmas, C; Sipsas, NV; Skopelitis, E; Tsavaris, N; Vadiaka, M; Ziakas, PD, 2007) |
| "The current study demonstrates that very carefully selected, low risk patients with febrile neutropenia may be treated successfully without hospitalization using oral ciprofloxacin." | 7.70 | Feasibility of oral ciprofloxacin for the outpatient management of febrile neutropenia in selected children with cancer. ( Aquino, VM; Buchanan, GR; Herrera, L; Sandler, ES, 2000) |
| "Hospitalized patients with sepsis caused by ciprofloxacin-susceptible organisms were treated with intravenous ciprofloxacin 300 mg every 12 hours." | 7.67 | Treatment of sepsis in patients with neoplastic diseases with intravenous ciprofloxacin. ( Brown, AE; Smith, G, 1989) |
| "Inclusion criteria were cancer, febrile neutropenia, low risk of complications as predicted by a Multinational Association for Supportive Care in Cancer (MASCC) score > 20, ability to swallow, and ≤ one single intravenous dose of empiric antibiotic therapy before study drug treatment initiation." | 6.78 | Oral antibiotics for fever in low-risk neutropenic patients with cancer: a double-blind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapy--EORTC infectiou ( Akan, H; Akova, M; Aoun, M; Calandra, T; de Bock, R; Drgona, L; Kern, WV; Marchetti, O; Paesmans, M; Viscoli, C, 2013) |
| "Pediatric cancer patients presenting with febrile neutropenia after non-myeloablative chemotherapy and who met institutional criteria for early hospital discharge following a minimum of 48-hr inpatient empiric intravenous ceftazidime were eligible for the study." | 6.71 | Ciprofloxacin and amoxicillin as continuation treatment of febrile neutropenia in pediatric cancer patients. ( Burns, JL; Coughlin, J; Friedman, DL; Hawkins, D; Park, JR; Pendergrass, T, 2003) |
| " The bioavailability of ciprofloxacin appeared comparable to that found in previously published studies of normal volunteers and patients not receiving chemotherapy." | 6.67 | Prophylaxis of bacterial infections with ciprofloxacin in patients undergoing bone marrow transplantation. ( Antman, KH; Finberg, R; Kalish, L; Kehoe, K; Lew, MA; Mayer, R; Nadler, L; Ritz, J; Takvorian, T, 1991) |
| "The incidence and of bacterial infections, and resulting mortality, among cancer patients is growing dramatically, worldwide." | 5.72 | Dual acting acid-cleavable self-assembling prodrug from hyaluronic acid and ciprofloxacin: A potential system for simultaneously targeting bacterial infections and cancer. ( Devnarain, N; Gafar, MA; Govender, T; Ibrahim, UH; Khan, R; Mocktar, C; Mohammed, M; Oh, JK; Omolo, CA; Pant, A; Salih, M; Shunmugam, L, 2022) |
| "Evaluation of benzylpenicillin (penicillin G) effect for infection prophylaxis at the oncological patients with severe postcytostatic neutropenia was performed." | 5.10 | [Benzylpenicillin efficacy for neutropenic infection prophylaxis in patients with cancer and postcytostatic neutropenia]. ( Chimishkian, KL; Dmitrieva, NV; Larionova, VB; Minenko, SV; Ptushkin, VV; Sokolova, EN; Zhukov, NV, 2002) |
| "In hospitalized low-risk patients who have fever and neutropenia during cancer chemotherapy, empirical therapy with oral ciprofloxacin and amoxicillin-clavulanate is safe and effective." | 5.09 | A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. ( Chanock, S; Freifeld, A; Gill, V; Hicks, JE; Hiemenz, J; Hiemenz, S; Lewis, L; Marchigiani, D; Pizzo, PA; Steinberg, SM; Walsh, T, 1999) |
| "The objective of this study was to test the efficacy of oral ciprofloxacin in the treatment of lower risk febrile neutropenia (LRFN) in children treated for malignant diseases." | 5.09 | Oral ciprofloxacin in the management of children with cancer with lower risk febrile neutropenia. ( Armada, A; Cáceres, E; Casimir, L; Debbag, R; Fernández, C; Firpo, V; Latella, A; Paganini, H; Rodriguez-Brieshcke, T; Zubizarreta, P, 2001) |
| "To determine whether the addition of rifampin to a quinolone-based antibacterial prophylactic regimen in patients undergoing high-dose chemotherapy (HDC) with peripheral-blood stem-cell transplantation (PBSCT) decreases the incidence of neutropenia and fever, Gram-positive bacteremia, and infection-related morbidity." | 5.09 | Rifampin does not improve the efficacy of quinolone antibacterial prophylaxis in neutropenic cancer patients: results of a randomized clinical trial. ( Arcediano, A; Cortés-Funes, H; Gomez-Martin, C; Hidalgo, M; Hornedo, J; Lumbreras, C; Perea, S; Rodriguez, M; Salazar, R; Solá, C; Valentí, V, 2000) |
| "Outpatient therapy with either oral ciprofloxacin or intravenous ceftriaxone for fever and neutropenia is effective and safe in pediatric patients with solid tumors and stage I/II non-Hodgkin lymphoma (low-risk patients)." | 5.09 | Oral ciprofloxacin vs. intravenous ceftriaxone administered in an outpatient setting for fever and neutropenia in low-risk pediatric oncology patients: randomized prospective trial. ( Campos, MC; Dantas, LS; Ginani, VC; Petrilli, AS; Seber, A; Tanaka, C, 2000) |
| "In low-risk patients with cancer who have fever and granulocytopenia, oral therapy with ciprofloxacin plus amoxicillin-clavulanate is as effective as intravenous therapy." | 5.09 | Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Can ( Cometta, A; De Bock, R; Gaya, H; Kern, WV; Langenaeken, J; Paesmans, M, 1999) |
| " The use of monotherapy with intravenous ciprofloxacin (200 to 300 mg every 12 h) was evaluated against combined therapy with piperacillin plus amikacin in febrile granulocytopenic patients with solid tumor or lymphoma." | 5.07 | Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors. The European Organization for Research on Treatment of Cancer ( Calandra, T; Gaya, H; Glauser, M; Klastersky, J; Meunier, F; Viscoli, C; Zinner, SH, 1991) |
| "To compare the effectiveness and toxicity of ciprofloxacin vs an aminoglycoside, both in combination with a beta-lactam, for the treatment of febrile neutropenia in the inpatient setting." | 4.82 | Ciprofloxacin vs an aminoglycoside in combination with a beta-lactam for the treatment of febrile neutropenia: a meta-analysis of randomized controlled trials. ( Bliziotis, IA; Christodoulou, C; Chrysanthopoulou, S; Falagas, ME; Kasiakou, SK; Michalopoulos, A; Samonis, G, 2005) |
| "The objective of this investigation was to assess retrospectively the safety and the efficacy of oral ciprofloxacin plus cefuroxime axetil compared to the combination of oral ciprofloxacin plus amoxicillin/clavulanate, as initial outpatient treatment, in low-risk cancer patients with fever and neutropenia." | 3.74 | Comparison of two oral regimens for the outpatient treatment of low-risk cancer patients with chemotherapy-induced neutropenia and fever: ciprofloxacin plus cefuroxime axetil versus ciprofloxacin plus amoxicillin/clavulanate. ( Karabelis, A; Kordossis, T; Kosmas, C; Sipsas, NV; Skopelitis, E; Tsavaris, N; Vadiaka, M; Ziakas, PD, 2007) |
| "The current study demonstrates that very carefully selected, low risk patients with febrile neutropenia may be treated successfully without hospitalization using oral ciprofloxacin." | 3.70 | Feasibility of oral ciprofloxacin for the outpatient management of febrile neutropenia in selected children with cancer. ( Aquino, VM; Buchanan, GR; Herrera, L; Sandler, ES, 2000) |
| "The susceptibility of clinical isolates of methicillin-susceptible and -resistant staphylococci from cancer patients with central venous catheter bacteremia to quinupristin/dalfopristin, a semisynthetic streptogramin, was determined in vitro." | 3.69 | In vitro study of the potential role of quinupristin/dalfopristin in the treatment of catheter-related staphylococcal infections. ( Garcia, R; Raad, I, 1996) |
| "Hospitalized patients with sepsis caused by ciprofloxacin-susceptible organisms were treated with intravenous ciprofloxacin 300 mg every 12 hours." | 3.67 | Treatment of sepsis in patients with neoplastic diseases with intravenous ciprofloxacin. ( Brown, AE; Smith, G, 1989) |
| "Inclusion criteria were cancer, febrile neutropenia, low risk of complications as predicted by a Multinational Association for Supportive Care in Cancer (MASCC) score > 20, ability to swallow, and ≤ one single intravenous dose of empiric antibiotic therapy before study drug treatment initiation." | 2.78 | Oral antibiotics for fever in low-risk neutropenic patients with cancer: a double-blind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapy--EORTC infectiou ( Akan, H; Akova, M; Aoun, M; Calandra, T; de Bock, R; Drgona, L; Kern, WV; Marchetti, O; Paesmans, M; Viscoli, C, 2013) |
| "We treated low-risk febrile neutropenic cancer patients utilizing two standard outpatient antibiotic pathways: oral ampicillin/clavulanate (500 mg) and ciprofloxacin (500 mg) or intravenous ceftazidime (2 g) and clindamycin (600 mg) every 8 h." | 2.71 | Outcomes of treatment pathways in outpatient treatment of low risk febrile neutropenic cancer patients. ( Badrina, N; Benjamin, R; DeJesus, Y; Escalante, CP; Fernandez, S; Ho, V; Lam, T; Lee, EL; Manzullo, E; Rivera, E; Rolston, K; Valdres, R; Weiser, MA, 2004) |
| "Pediatric cancer patients presenting with febrile neutropenia after non-myeloablative chemotherapy and who met institutional criteria for early hospital discharge following a minimum of 48-hr inpatient empiric intravenous ceftazidime were eligible for the study." | 2.71 | Ciprofloxacin and amoxicillin as continuation treatment of febrile neutropenia in pediatric cancer patients. ( Burns, JL; Coughlin, J; Friedman, DL; Hawkins, D; Park, JR; Pendergrass, T, 2003) |
| " The bioavailability of ciprofloxacin appeared comparable to that found in previously published studies of normal volunteers and patients not receiving chemotherapy." | 2.67 | Prophylaxis of bacterial infections with ciprofloxacin in patients undergoing bone marrow transplantation. ( Antman, KH; Finberg, R; Kalish, L; Kehoe, K; Lew, MA; Mayer, R; Nadler, L; Ritz, J; Takvorian, T, 1991) |
| "The global pandemic of drug-sensitive cancers and the increasing threat from drug-resistant cancers make an urgent need to develop more effective anti-cancer candidates." | 2.61 | Quinolone hybrids and their anti-cancer activities: An overview. ( Gao, F; Wang, T; Xiao, J; Zhang, X, 2019) |
| "Ciprofloxacin (CP) is a fluoroquinolone that is highly active against diverse microorganisms." | 2.49 | Medicinal potential of ciprofloxacin and its derivatives. ( Biot, C; Castro, W; Navarro, M, 2013) |
| "Thus, up to date management of cancer patients, in addition to other supportive care modalities, should also incorporate diagnostic methods and therapy of infections." | 2.47 | [Treatment and prevention of infections in cancer patients with neutropenia]. ( Sinkó, J, 2011) |
| "Patients who are treated for acute leukemia should be offered prophylaxis with ciprofloxacin or levofloxacin." | 2.43 | Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions. ( Bucaneve, G; Cullen, M; Fraser, A; Gafter-Gvili, A; Kern, WV; Leibovici, L; Paul, M, 2006) |
| "In general, patients with Crohn's disease are not usually offered IPAA, because recurrence of disease, fistulas, abscesses, and strictures may lead to a higher incidence of pouch failure." | 2.41 | Complications after ileal pouch-anal anastomosis. ( Lichtenstein, GR; Stein, RB, 2000) |
| "Allergic interstitial nephritis is believed to be the underlying pathological-process." | 2.38 | Ciprofloxacin-induced nephrotoxicity in patients with cancer. ( Bodey, GP; Lo, WK; Rolston, KV; Rubenstein, EB, 1993) |
| "Ciprofloxacin is a fluoroquinolone, widely used because of its broad spectrum antimicrobial activity and favorable pharmacokinetic properties." | 1.91 | Administration of ciprofloxacin through a nasogastric tube in pediatric oncology and stem cell transplantation patients. ( Bauters, T; Buyle, F; Dhooge, C; Schelstraete, P, 2023) |
| "The incidence and of bacterial infections, and resulting mortality, among cancer patients is growing dramatically, worldwide." | 1.72 | Dual acting acid-cleavable self-assembling prodrug from hyaluronic acid and ciprofloxacin: A potential system for simultaneously targeting bacterial infections and cancer. ( Devnarain, N; Gafar, MA; Govender, T; Ibrahim, UH; Khan, R; Mocktar, C; Mohammed, M; Oh, JK; Omolo, CA; Pant, A; Salih, M; Shunmugam, L, 2022) |
| "Antimicrobial resistance and cancer are two important problems affecting human health." | 1.62 | Antibacterial and antitumoral properties of 1,2,3-triazolo fused triterpenes and their mechanism of inhibiting the proliferation of HL-60 cells. ( Daelemans, D; De Jonghe, S; Dehaen, W; Hu, H; Krasniqi, B; Li, Y; Luyten, W; Persoons, L; Wang, R, 2021) |
| "Interestingly, cancer stem cell counts increased significantly in the presence of EB." | 1.62 | The effects of biofilms on tumor progression in a 3D cancer-biofilm microfluidic model. ( Chua, SL; Deng, Y; Khoo, BL; Liu, SY, 2021) |
| "Febrile neutropenia: is ambulatory care possible ? Outpatient treatment of neutropenic fever post chemotherapy is possible for patients at low risk of complications." | 1.46 | [Febrile neutropenia: is ambulatory care possible]? ( Lafaurie, M, 2017) |
| "The primary in vitro one dose anticancer assay experienced promising cytotoxic activity against different cancer cell lines especially non-small cell lung cancer." | 1.43 | New antiproliferative 7-(4-(N-substituted carbamoylmethyl)piperazin-1-yl) derivatives of ciprofloxacin induce cell cycle arrest at G2/M phase. ( Abbas, SH; Abd El-Hafeez, AA; Abdelhafez, EMN; Abuo-Rahma, GEA; Mohammed, HHH, 2016) |
| "Ciprofloxacin resistance was more frequent in children who shared an environment with adults who were receiving ciprofloxacin prophylaxis." | 1.33 | Differences in the proportions of fluoroquinolone-resistant Gram-negative bacteria isolated from bacteraemic children with cancer in two Italian centres. ( Castagnola, E; Caviglia, I; Giona, F; Girmenia, C; Haupt, R; Micozzi, A; Parodi, S; Testi, AM, 2005) |
| "Trovafloxacin was also the most active agent tested against Gram-positive organisms, including ciprofloxacin-susceptible strains and most ciprofloxacin- and methicillin-resistant staphylococci and enterococci." | 1.30 | In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer. ( Dvorak, T; Ho, DH; LeBlanc, B; Rolston, KV; Streeter, H, 1997) |
| "No bacteremia was noted." | 1.29 | Prophylactic antibiotics eliminate bacteremia and allow safe outpatient management following high-dose chemotherapy and autologous stem cell rescue. ( Brehm, T; Gollard, R; McMillan, R; Meisenberg, B; Miller, W, 1996) |
| "Sparfloxacin was extremely active against Acinetobacter species, Aeromonas hydrophila, Citrobacter diversus, Enterobacter species, Escherichia coli, Klebsiella species, Proteus vulgaris, and Serratia marcescens (inhibiting greater than 90% of these isolates at a concentration of 0." | 1.28 | In vitro activity of sparfloxacin (CI-978; AT-4140) against clinical isolates from cancer patients. ( Bodey, GP; Ho, DH; LeBlanc, B; Messer, M; Nguyen, H; Rolston, KV, 1990) |
| "Forty six episodes of infection in 43 cancer patients were treated with oral ciprofloxacin at a dose of 750 mg every 8 h." | 1.28 | Oral ciprofloxacin therapy for infections in cancer patients. ( Bodey, GP; Cunningham, C; Haron, E; Holmes, F; Rolston, KV; Umsawasdi, T, 1989) |
| "One hundred forty-seven cancer patients were treated with intravenously administered ciprofloxacin, 200 mg every eight hours, as initial therapy for febrile episodes." | 1.28 | Intravenous ciprofloxacin for infections in cancer patients. ( Bodey, GP; Cunningham, C; Haron, E; Rolston, KV, 1989) |
| "Ciprofloxacin results to be an effective antibacterial agent in a high risk population." | 1.27 | Treatment of infections in non-neutropenic patients with cancer, AIDS, or renal transplant using ciprofloxacin. ( Bianchi, W; Maggiolo, F; Ohnmeiss, H, 1988) |
| "Sch 34343 was extremely active against beta-haemolytic streptococci (Lancefield groups A, B and G) with MIC90s ranging from 0." | 1.27 | In-vitro activity of Sch 34343, a new penam, against gram-positive isolates from cancer patients. ( Alderman, HC; Alvarez, ME; Bodey, GP; Ho, DH; Hoy, JF; Rolston, KV, 1986) |
| "Fleroxacin was also active against group JK-diphtheroids and Bacillus cereus." | 1.27 | In vitro activity of fleroxacin (Ro23-6240), a new fluorinated 4-quinolone against isolates from cancer patients. ( Bodey, GP; Ho, DH; LeBlanc, B; Rolston, K, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (14.29) | 18.7374 |
| 1990's | 31 (31.63) | 18.2507 |
| 2000's | 21 (21.43) | 29.6817 |
| 2010's | 22 (22.45) | 24.3611 |
| 2020's | 10 (10.20) | 2.80 |
| Authors | Studies |
|---|---|
| Azéma, J | 2 |
| Guidetti, B | 2 |
| Dewelle, J | 1 |
| Le Calve, B | 1 |
| Mijatovic, T | 1 |
| Korolyov, A | 2 |
| Vaysse, J | 1 |
| Malet-Martino, M | 2 |
| Martino, R | 1 |
| Kiss, R | 2 |
| Antczak, C | 1 |
| Shum, D | 1 |
| Bassit, B | 1 |
| Frattini, MG | 1 |
| Li, Y | 3 |
| de Stanchina, E | 1 |
| Scheinberg, DA | 1 |
| Djaballah, H | 1 |
| Roques, C | 1 |
| Constant, P | 1 |
| Daffé, M | 1 |
| Jahnsen, RD | 1 |
| Sandberg-Schaal, A | 1 |
| Vissing, KJ | 1 |
| Nielsen, HM | 1 |
| Frimodt-Møller, N | 1 |
| Franzyk, H | 1 |
| Lin, R | 1 |
| Elf, S | 1 |
| Shan, C | 1 |
| Kang, HB | 1 |
| Ji, Q | 1 |
| Zhou, L | 1 |
| Hitosugi, T | 1 |
| Zhang, L | 1 |
| Zhang, S | 1 |
| Seo, JH | 1 |
| Xie, J | 1 |
| Tucker, M | 1 |
| Gu, TL | 1 |
| Sudderth, J | 1 |
| Jiang, L | 1 |
| Mitsche, M | 1 |
| DeBerardinis, RJ | 1 |
| Wu, S | 1 |
| Mao, H | 1 |
| Chen, PR | 1 |
| Wang, D | 1 |
| Chen, GZ | 1 |
| Hurwitz, SJ | 1 |
| Lonial, S | 1 |
| Arellano, ML | 1 |
| Khoury, HJ | 1 |
| Khuri, FR | 1 |
| Lee, BH | 1 |
| Lei, Q | 1 |
| Brat, DJ | 1 |
| Ye, K | 1 |
| Boggon, TJ | 1 |
| He, C | 1 |
| Kang, S | 1 |
| Fan, J | 1 |
| Chen, J | 1 |
| Venepally, V | 1 |
| Prasad, RBN | 1 |
| Poornachandra, Y | 1 |
| Kumar, CG | 1 |
| Jala, RCR | 1 |
| Mohammed, HHH | 1 |
| Abd El-Hafeez, AA | 1 |
| Abbas, SH | 1 |
| Abdelhafez, EMN | 1 |
| Abuo-Rahma, GEA | 1 |
| Febles, M | 1 |
| Montalvão, S | 1 |
| Crespín, GD | 1 |
| Norte, M | 1 |
| Padrón, JM | 1 |
| Tammela, P | 1 |
| Fernández, JJ | 1 |
| Daranas, AH | 1 |
| Pluta, K | 1 |
| Jeleń, M | 1 |
| Morak-Młodawska, B | 1 |
| Zimecki, M | 1 |
| Artym, J | 1 |
| Kocięba, M | 1 |
| Zaczyńska, E | 1 |
| Chu, XM | 1 |
| Wang, C | 1 |
| Liu, W | 1 |
| Liang, LL | 1 |
| Gong, KK | 1 |
| Zhao, CY | 1 |
| Sun, KL | 1 |
| Gao, F | 1 |
| Zhang, X | 1 |
| Wang, T | 1 |
| Xiao, J | 1 |
| Wang, R | 1 |
| Hu, H | 1 |
| Persoons, L | 1 |
| Daelemans, D | 1 |
| De Jonghe, S | 1 |
| Luyten, W | 1 |
| Krasniqi, B | 1 |
| Dehaen, W | 1 |
| Caldwell, L | 1 |
| Bapat, A | 1 |
| Drumright, LN | 1 |
| Lambourne, J | 1 |
| Jimenez-England, FG | 1 |
| Aries, J | 1 |
| Eccersley, L | 1 |
| Hallam, S | 1 |
| Montoto, S | 1 |
| Oakervee, H | 1 |
| Riches, J | 1 |
| Agrawal, SG | 1 |
| Suaifan, GARY | 1 |
| Mohammed, AAM | 1 |
| Alkhawaja, BA | 1 |
| Matta-Chuquisapon, J | 1 |
| Valencia-Bazalar, E | 1 |
| Sevilla-Andrade, C | 1 |
| Barrón-Pastor, HJ | 1 |
| Ibrahim, UH | 1 |
| Devnarain, N | 1 |
| Mohammed, M | 1 |
| Omolo, CA | 1 |
| Gafar, MA | 1 |
| Salih, M | 1 |
| Pant, A | 1 |
| Shunmugam, L | 1 |
| Mocktar, C | 1 |
| Khan, R | 1 |
| Oh, JK | 1 |
| Govender, T | 1 |
| Alaaeldin, R | 3 |
| Abdel-Rahman, IM | 3 |
| Ali, FEM | 3 |
| Bekhit, AA | 3 |
| Elhamadany, EY | 3 |
| Zhao, QL | 3 |
| Cui, ZG | 3 |
| Fathy, M | 3 |
| Bauters, T | 1 |
| Buyle, F | 1 |
| Schelstraete, P | 1 |
| Dhooge, C | 1 |
| Forde, C | 1 |
| McMullan, R | 1 |
| Clarke, M | 1 |
| Wilson, RH | 1 |
| Plummer, R | 1 |
| Grayson, M | 1 |
| McDowell, C | 1 |
| Agus, A | 1 |
| Doran, A | 1 |
| McAuley, DF | 1 |
| Thomas, AL | 1 |
| Barnes, RA | 1 |
| Adams, R | 1 |
| Chau, I | 1 |
| Coyle, V | 1 |
| Deng, Y | 1 |
| Liu, SY | 1 |
| Chua, SL | 1 |
| Khoo, BL | 1 |
| Wang, DY | 1 |
| Yang, G | 1 |
| van der Mei, HC | 1 |
| Ren, Y | 1 |
| Busscher, HJ | 1 |
| Shi, L | 1 |
| Sang, Q | 1 |
| Li, H | 1 |
| Williams, G | 1 |
| Wu, H | 1 |
| Zhu, LM | 1 |
| Hamed, SM | 2 |
| Aboshanab, KMA | 2 |
| El-Mahallawy, HA | 2 |
| Helmy, MM | 2 |
| Ashour, MS | 2 |
| Elkhatib, WF | 2 |
| Lafaurie, M | 1 |
| Gupta, P | 1 |
| Gao, HL | 1 |
| Ashar, YV | 1 |
| Karadkhelkar, NM | 1 |
| Yoganathan, S | 1 |
| Chen, ZS | 1 |
| Fu, Y | 1 |
| Yang, Y | 1 |
| Zhou, S | 1 |
| Liu, Y | 1 |
| Yuan, Y | 1 |
| Li, S | 1 |
| Li, C | 1 |
| Borget, I | 1 |
| Antoun, S | 1 |
| Chachaty, E | 1 |
| Gachot, B | 1 |
| Alibay, A | 1 |
| Di Palma, M | 1 |
| Merad, M | 1 |
| Srinivasan, A | 1 |
| Seifried, S | 1 |
| Zhu, L | 1 |
| Srivastava, DK | 1 |
| Flynn, PM | 1 |
| Shenep, JL | 1 |
| Bankowski, MJ | 1 |
| Hayden, RT | 1 |
| Sinkó, J | 1 |
| Castro, W | 1 |
| Navarro, M | 1 |
| Biot, C | 1 |
| Slavin, MA | 1 |
| Thursky, KA | 1 |
| Kern, WV | 3 |
| Marchetti, O | 1 |
| Drgona, L | 1 |
| Akan, H | 1 |
| Aoun, M | 1 |
| Akova, M | 1 |
| de Bock, R | 2 |
| Paesmans, M | 2 |
| Viscoli, C | 2 |
| Calandra, T | 2 |
| Schelenz, S | 1 |
| Nwaka, D | 1 |
| Hunter, PR | 1 |
| Park, JR | 1 |
| Coughlin, J | 1 |
| Hawkins, D | 1 |
| Friedman, DL | 1 |
| Burns, JL | 1 |
| Pendergrass, T | 1 |
| Minenko, SV | 1 |
| Dmitrieva, NV | 1 |
| Chimishkian, KL | 1 |
| Zhukov, NV | 1 |
| Sokolova, EN | 1 |
| Larionova, VB | 1 |
| Ptushkin, VV | 1 |
| Mullen, CA | 2 |
| Cometta, A | 2 |
| Kern, W | 1 |
| Ammann, RA | 1 |
| Escalante, CP | 1 |
| Weiser, MA | 1 |
| Manzullo, E | 2 |
| Benjamin, R | 1 |
| Rivera, E | 1 |
| Lam, T | 1 |
| Ho, V | 1 |
| Valdres, R | 1 |
| Lee, EL | 1 |
| Badrina, N | 1 |
| Fernandez, S | 1 |
| DeJesus, Y | 1 |
| Rolston, K | 3 |
| Castagnola, E | 1 |
| Haupt, R | 1 |
| Micozzi, A | 2 |
| Caviglia, I | 1 |
| Testi, AM | 1 |
| Giona, F | 1 |
| Parodi, S | 1 |
| Girmenia, C | 1 |
| Paul, M | 2 |
| Leibovici, L | 2 |
| Bliziotis, IA | 1 |
| Michalopoulos, A | 1 |
| Kasiakou, SK | 1 |
| Samonis, G | 1 |
| Christodoulou, C | 1 |
| Chrysanthopoulou, S | 1 |
| Falagas, ME | 1 |
| Nemes, G | 1 |
| Heuser, Y | 1 |
| Stolle, D | 1 |
| Piroth, HD | 1 |
| Nemes, P | 1 |
| Beno, P | 1 |
| Krcmery, V | 2 |
| Demitrovicova, A | 1 |
| Cullen, M | 1 |
| Bucaneve, G | 2 |
| Gafter-Gvili, A | 1 |
| Fraser, A | 1 |
| Sipsas, NV | 1 |
| Kosmas, C | 1 |
| Ziakas, PD | 1 |
| Karabelis, A | 1 |
| Vadiaka, M | 1 |
| Skopelitis, E | 1 |
| Kordossis, T | 1 |
| Tsavaris, N | 1 |
| Garcia, I | 1 |
| Bodey, GP | 16 |
| Fainstein, V | 1 |
| Ho, DH | 12 |
| LeBlanc, B | 11 |
| Bennett, CL | 1 |
| Smith, TJ | 1 |
| George, SL | 1 |
| Hillner, BE | 1 |
| Fleishman, S | 1 |
| Niell, HB | 1 |
| Velasco, E | 1 |
| Costa, MA | 1 |
| Martins, CA | 1 |
| Nucci, M | 1 |
| Maiche, AG | 1 |
| Muhonen, T | 1 |
| Dholakia, N | 1 |
| Rolston, KV | 16 |
| Del Favero, A | 2 |
| Menichetti, F | 2 |
| Rubenstein, EB | 2 |
| Benjamin, RS | 1 |
| Loewy, J | 1 |
| Escalante, C | 1 |
| Hughes, P | 1 |
| Moreland, B | 1 |
| Fender, A | 1 |
| Kennedy, K | 1 |
| Lo, WK | 1 |
| Hachem, R | 1 |
| Raad, I | 2 |
| Whimbey, E | 1 |
| Katz, R | 1 |
| Tarrand, J | 1 |
| Libshitz, H | 1 |
| Styler, MJ | 1 |
| Crilley, P | 1 |
| Biggs, J | 1 |
| Moul, J | 1 |
| Copelan, E | 1 |
| Topolsky, D | 1 |
| Avalos, B | 1 |
| Penza, S | 1 |
| Sabol, P | 1 |
| Downs, K | 1 |
| Szer, J | 1 |
| Brodsky, I | 1 |
| Marks, DI | 1 |
| Meisenberg, B | 1 |
| Gollard, R | 1 |
| Brehm, T | 1 |
| McMillan, R | 1 |
| Miller, W | 1 |
| Freifeld, A | 2 |
| Pizzo, P | 1 |
| Garcia, R | 1 |
| Hidalgo, M | 3 |
| Hornedo, J | 3 |
| Lumbreras, C | 3 |
| Trigo, JM | 1 |
| Gómez, C | 2 |
| Perea, S | 3 |
| Ruiz, A | 1 |
| Hitt, R | 1 |
| Cortés-Funes, H | 3 |
| Streeter, H | 1 |
| Dvorak, T | 1 |
| Murphy, M | 1 |
| Brown, AE | 2 |
| Sepkowitz, KA | 1 |
| Bernard, EM | 1 |
| Kiehn, TE | 1 |
| Armstrong, D | 1 |
| Salazar, R | 2 |
| Solá, C | 2 |
| Maroto, P | 1 |
| Tabernero, JM | 1 |
| Brunet, J | 1 |
| Verger, G | 1 |
| Valentí, V | 2 |
| Cancelas, JA | 1 |
| Ojeda, B | 1 |
| Mendoza, L | 1 |
| Rodríguez, M | 2 |
| Montesinos, J | 1 |
| López-López, JJ | 1 |
| Minotti, V | 1 |
| Gentile, G | 1 |
| Iori, AP | 1 |
| Cavicchi, F | 1 |
| Barbabietola, G | 1 |
| Landonio, G | 1 |
| Martino, P | 1 |
| Petropoulos, D | 1 |
| Roberts, WM | 1 |
| Rytting, M | 1 |
| Zipf, T | 1 |
| Chan, KW | 1 |
| Culbert, SJ | 1 |
| Danielson, M | 1 |
| Jeha, SS | 1 |
| Kuttesch, JF | 1 |
| Marchigiani, D | 1 |
| Walsh, T | 1 |
| Chanock, S | 1 |
| Lewis, L | 1 |
| Hiemenz, J | 1 |
| Hiemenz, S | 1 |
| Hicks, JE | 1 |
| Gill, V | 1 |
| Steinberg, SM | 1 |
| Pizzo, PA | 1 |
| Langenaeken, J | 1 |
| Gaya, H | 2 |
| Arcediano, A | 2 |
| Ramos, MJ | 1 |
| Folgueira, D | 1 |
| Rodriguez-Noriega, A | 1 |
| Antabli, BA | 1 |
| Bross, P | 1 |
| Siegel, RS | 1 |
| Small, CD | 1 |
| Tabbara, IA | 1 |
| Petrilli, AS | 1 |
| Dantas, LS | 1 |
| Campos, MC | 1 |
| Tanaka, C | 1 |
| Ginani, VC | 1 |
| Seber, A | 1 |
| Stein, RB | 1 |
| Lichtenstein, GR | 1 |
| Aquino, VM | 1 |
| Herrera, L | 1 |
| Sandler, ES | 1 |
| Buchanan, GR | 1 |
| Gomez-Martin, C | 1 |
| Paganini, H | 2 |
| Rodriguez-Brieshcke, T | 1 |
| Zubizarreta, P | 2 |
| Latella, A | 1 |
| Firpo, V | 1 |
| Casimir, L | 1 |
| Armada, A | 1 |
| Fernández, C | 1 |
| Cáceres, E | 1 |
| Debbag, R | 1 |
| Drusano, GL | 1 |
| Meunier, F | 1 |
| Zinner, SH | 1 |
| Klastersky, J | 1 |
| Glauser, M | 1 |
| Messer, M | 2 |
| Nguyen, H | 2 |
| Ho, D | 1 |
| Lew, MA | 1 |
| Kehoe, K | 1 |
| Ritz, J | 1 |
| Antman, KH | 1 |
| Nadler, L | 1 |
| Takvorian, T | 1 |
| Mayer, R | 1 |
| Kalish, L | 1 |
| Finberg, R | 1 |
| Dronova, OM | 1 |
| Horníková, M | 1 |
| Koza, I | 1 |
| Fuchsberger, P | 1 |
| Spánik, S | 1 |
| Sufliarsky, J | 1 |
| Mardiak, J | 1 |
| Sitáni, L | 1 |
| Milosovic, P | 1 |
| Haron, E | 2 |
| Cunningham, C | 2 |
| Holmes, F | 1 |
| Umsawasdi, T | 1 |
| Smith, G | 1 |
| Elting, L | 1 |
| Maggiolo, F | 1 |
| Bianchi, W | 1 |
| Ohnmeiss, H | 1 |
| Alvarez, ME | 2 |
| Hoy, JF | 1 |
| Alderman, HC | 1 |
| Gooch, G | 1 |
| Dennig, D | 1 |
| Fülle, HH | 1 |
| Hellriegel, KP | 1 |
| Hsu, KC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Oral Empirical Therapy of Fever in Low-Risk Neutropenic Cancer Patients: A Prospective, Double-Blind, Randomized, Multicenter Trial Comparing Monotherapy (Single Daily Dose Moxifloxacin) With Combination Therapy (Ciprofloxacin Plus Amoxicillin/Clavulanic [NCT00062231] | 351 participants (Actual) | Interventional | 2002-04-30 | Terminated (stopped due to low accrual) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
14 reviews available for ciprofloxacin and Benign Neoplasms
| Article | Year |
|---|---|
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; | 2015 |
Azaphenothiazines - promising phenothiazine derivatives. An insight into nomenclature, synthesis, structure elucidation and biological properties.
Topics: Animals; Anti-Bacterial Agents; Antifungal Agents; Antineoplastic Agents; Antiprotozoal Agents; Anti | 2017 |
Quinoline and quinolone dimers and their biological activities: An overview.
Topics: Anti-Bacterial Agents; Antimalarials; Antineoplastic Agents; Bacteria; Dimerization; Humans; Neoplas | 2019 |
Quinolone hybrids and their anti-cancer activities: An overview.
Topics: Animals; Antineoplastic Agents; Humans; Neoplasms; Quinolones; Structure-Activity Relationship | 2019 |
Fluoroquinolones' Biological Activities against Laboratory Microbes and Cancer Cell Lines.
Topics: Anti-Bacterial Agents; Bacteria; Cell Line; Ciprofloxacin; Fluoroquinolones; Microbial Sensitivity T | 2022 |
[Treatment and prevention of infections in cancer patients with neutropenia].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antifungal Agents; Antineoplastic Agents; Bacterial In | 2011 |
Medicinal potential of ciprofloxacin and its derivatives.
Topics: Acquired Immunodeficiency Syndrome; Anti-Bacterial Agents; Ciprofloxacin; Humans; Malaria, Falciparu | 2013 |
Ciprofloxacin in treatment of fever and neutropenia in pediatric cancer patients.
Topics: Ambulatory Care; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Bacterial I | 2003 |
[Treatment with oral antibiotics of febrile neutropenia in onco-haematology. The experience of the EORTC antimicrobial group].
Topics: Administration, Oral; Amoxicillin-Potassium Clavulanate Combination; Bacterial Infections; Ceftazidi | 2004 |
Ciprofloxacin vs an aminoglycoside in combination with a beta-lactam for the treatment of febrile neutropenia: a meta-analysis of randomized controlled trials.
Topics: Aminoglycosides; Anti-Bacterial Agents; beta-Lactams; Ciprofloxacin; Drug Therapy, Combination; Feve | 2005 |
Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions.
Topics: Acute Disease; Antibiotic Prophylaxis; Antineoplastic Agents; Bone Marrow Transplantation; Ciproflox | 2006 |
Free-riding and the prisoner's dilemma: problems in funding economic analyses of phase III cancer clinical trials.
Topics: Carcinoma, Non-Small-Cell Lung; Ciprofloxacin; Clinical Trials, Phase III as Topic; Cost-Benefit Ana | 1995 |
Ciprofloxacin-induced nephrotoxicity in patients with cancer.
Topics: Acute Kidney Injury; Aged; Ciprofloxacin; Female; Fever; Humans; Kidney; Male; Middle Aged; Neoplasm | 1993 |
Complications after ileal pouch-anal anastomosis.
Topics: Anastomosis, Surgical; Ciprofloxacin; Colitis, Ulcerative; Crohn Disease; Humans; Male; Metronidazol | 2000 |
19 trials available for ciprofloxacin and Benign Neoplasms
| Article | Year |
|---|---|
Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis (the EASI-SWITCH trial): study protocol for a randomised controlled trial.
Topics: Administration, Intravenous; Administration, Oral; Amoxicillin-Potassium Clavulanate Combination; An | 2020 |
Oral antibiotics for fever in low-risk neutropenic patients with cancer: a double-blind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapy--EORTC infectiou
Topics: Administration, Oral; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Ag | 2013 |
Ciprofloxacin and amoxicillin as continuation treatment of febrile neutropenia in pediatric cancer patients.
Topics: Administration, Oral; Ambulatory Care; Amoxicillin; Antineoplastic Agents; Blood Cell Count; Child; | 2003 |
[Benzylpenicillin efficacy for neutropenic infection prophylaxis in patients with cancer and postcytostatic neutropenia].
Topics: Adolescent; Adult; Anti-Infective Agents; Antibiotic Prophylaxis; Antineoplastic Agents; Bacterial I | 2002 |
Outcomes of treatment pathways in outpatient treatment of low risk febrile neutropenic cancer patients.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Ampicillin; Anti-Bacterial Agents; Cancer Care Facilities; | 2004 |
Randomized trial comparing oral ciprofloxacin plus penicillin V with amikacin plus carbenicillin or ceftazidime for empirical treatment of febrile neutropenic cancer patients.
Topics: Administration, Oral; Adult; Amikacin; Carbenicillin; Ceftazidime; Ciprofloxacin; Costs and Cost Ana | 1995 |
Granulocyte colony-stimulating factor (G-CSF) with or without a quinolone in the prevention of infection in cancer patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; Ciprofloxacin; Female; Granulocyte | 1993 |
Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer.
Topics: Administration, Oral; Adolescent; Adult; Aged; Ambulatory Care; Aztreonam; Bacteremia; Bacterial Inf | 1993 |
Lack of ability of ciprofloxacin-rifampin prophylaxis to decrease infection-related morbidity in neutropenic patients given cytotoxic therapy and peripheral blood stem cell transplants.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics, Antitubercular; Antineoplastic Com | 1997 |
Domiciliary treatment of febrile episodes in cancer patients: a prospective randomized trial comparing oral versus parenteral empirical antibiotic treatment.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacterial Infections; C | 1999 |
Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients.
Topics: Adolescent; Ambulatory Care; Antineoplastic Agents; Bacterial Infections; Ceftazidime; Cephalosporin | 1999 |
A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy.
Topics: Administration, Oral; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Antineoplastic Ag | 1999 |
Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Can
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Agranulocytosis; Amikacin; Amoxici | 1999 |
Empiric antimicrobial therapy of febrile neutropenic patients undergoing haematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Bacterial Infections; Bone Marrow Transplantation; C | 1999 |
Oral ciprofloxacin vs. intravenous ceftriaxone administered in an outpatient setting for fever and neutropenia in low-risk pediatric oncology patients: randomized prospective trial.
Topics: Administration, Oral; Adolescent; Adult; Ambulatory Care; Anti-Infective Agents; Antineoplastic Agen | 2000 |
Rifampin does not improve the efficacy of quinolone antibacterial prophylaxis in neutropenic cancer patients: results of a randomized clinical trial.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics, Antitubercular; Antineoplastic Age | 2000 |
Oral ciprofloxacin in the management of children with cancer with lower risk febrile neutropenia.
Topics: Administration, Oral; Adolescent; Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Antineopla | 2001 |
Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors. The European Organization for Research on Treatment of Cancer
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Amikacin; Bacterial Infections; Ciprofloxacin; Drug | 1991 |
Prophylaxis of bacterial infections with ciprofloxacin in patients undergoing bone marrow transplantation.
Topics: Adult; Bacterial Infections; Biological Availability; Bone Marrow Transplantation; Ciprofloxacin; Fe | 1991 |
65 other studies available for ciprofloxacin and Benign Neoplasms
| Article | Year |
|---|---|
7-((4-Substituted)piperazin-1-yl) derivatives of ciprofloxacin: synthesis and in vitro biological evaluation as potential antitumor agents.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Ciprofloxacin; Humans; Maximum | 2009 |
Identification of benzofuran-4,5-diones as novel and selective non-hydroxamic acid, non-peptidomimetic based inhibitors of human peptide deformylase.
Topics: Amidohydrolases; Animals; Antineoplastic Agents; Benzofurans; Cell Line, Tumor; Drug Screening Assay | 2011 |
Synthesis of lipophilic dimeric C-7/C-7-linked ciprofloxacin and C-6/C-6-linked levofloxacin derivatives. Versatile in vitro biological evaluations of monomeric and dimeric fluoroquinolone derivatives as potential antitumor, antibacterial or antimycobacte
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Bacteria; Bacterial Infections; Cell Line, Tumor; Cipr | 2011 |
Tailoring cytotoxicity of antimicrobial peptidomimetics with high activity against multidrug-resistant Escherichia coli.
Topics: Anti-Bacterial Agents; Antimicrobial Cationic Peptides; Antineoplastic Agents; Cell Proliferation; C | 2014 |
Synthesis of novel ethyl 1-ethyl-6-fluoro-7-(fatty amido)-1,4-dihydro-4-oxoquinoline-3-carboxylate derivatives and their biological evaluation.
Topics: 4-Quinolones; Anti-Bacterial Agents; Anti-Infective Agents; Antineoplastic Agents; Antioxidants; Bac | 2016 |
New antiproliferative 7-(4-(N-substituted carbamoylmethyl)piperazin-1-yl) derivatives of ciprofloxacin induce cell cycle arrest at G2/M phase.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cel | 2016 |
Synthesis and biological evaluation of crown ether acyl derivatives.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antifungal Agents; Antineoplastic Agents; Candida albi | 2016 |
Antibacterial and antitumoral properties of 1,2,3-triazolo fused triterpenes and their mechanism of inhibiting the proliferation of HL-60 cells.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Cell Proliferation; HL-60 Cells; Humans; Molecular Str | 2021 |
Cessation of Ciprofloxacin Prophylaxis in Hemato-Oncology Patients.
Topics: Antibiotic Prophylaxis; Ciprofloxacin; Humans; Neoplasms | 2022 |
Phylogeny and antimicrobial resistance of extended-spectrum beta-lactamaseproducing Escherichia coli from hospitalized oncology patients in Perú
Topics: Anti-Bacterial Agents; beta-Lactamases; Ciprofloxacin; Cross-Sectional Studies; Drug Resistance, Bac | 2022 |
Dual acting acid-cleavable self-assembling prodrug from hyaluronic acid and ciprofloxacin: A potential system for simultaneously targeting bacterial infections and cancer.
Topics: Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Drug Delivery Systems; Humans; Hyaluroni | 2022 |
Dual Topoisomerase I/II Inhibition-Induced Apoptosis and Necro-Apoptosis in Cancer Cells by a Novel Ciprofloxacin Derivative via RIPK1/RIPK3/MLKL Activation.
Topics: Apoptosis; Ciprofloxacin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Molecular Docking | 2022 |
Dual Topoisomerase I/II Inhibition-Induced Apoptosis and Necro-Apoptosis in Cancer Cells by a Novel Ciprofloxacin Derivative via RIPK1/RIPK3/MLKL Activation.
Topics: Apoptosis; Ciprofloxacin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Molecular Docking | 2022 |
Dual Topoisomerase I/II Inhibition-Induced Apoptosis and Necro-Apoptosis in Cancer Cells by a Novel Ciprofloxacin Derivative via RIPK1/RIPK3/MLKL Activation.
Topics: Apoptosis; Ciprofloxacin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Molecular Docking | 2022 |
Dual Topoisomerase I/II Inhibition-Induced Apoptosis and Necro-Apoptosis in Cancer Cells by a Novel Ciprofloxacin Derivative via RIPK1/RIPK3/MLKL Activation.
Topics: Apoptosis; Ciprofloxacin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Molecular Docking | 2022 |
Dual Topoisomerase I/II Inhibition-Induced Apoptosis and Necro-Apoptosis in Cancer Cells by a Novel Ciprofloxacin Derivative via RIPK1/RIPK3/MLKL Activation.
Topics: Apoptosis; Ciprofloxacin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Molecular Docking | 2022 |
Dual Topoisomerase I/II Inhibition-Induced Apoptosis and Necro-Apoptosis in Cancer Cells by a Novel Ciprofloxacin Derivative via RIPK1/RIPK3/MLKL Activation.
Topics: Apoptosis; Ciprofloxacin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Molecular Docking | 2022 |
Dual Topoisomerase I/II Inhibition-Induced Apoptosis and Necro-Apoptosis in Cancer Cells by a Novel Ciprofloxacin Derivative via RIPK1/RIPK3/MLKL Activation.
Topics: Apoptosis; Ciprofloxacin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Molecular Docking | 2022 |
Dual Topoisomerase I/II Inhibition-Induced Apoptosis and Necro-Apoptosis in Cancer Cells by a Novel Ciprofloxacin Derivative via RIPK1/RIPK3/MLKL Activation.
Topics: Apoptosis; Ciprofloxacin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Molecular Docking | 2022 |
Dual Topoisomerase I/II Inhibition-Induced Apoptosis and Necro-Apoptosis in Cancer Cells by a Novel Ciprofloxacin Derivative via RIPK1/RIPK3/MLKL Activation.
Topics: Apoptosis; Ciprofloxacin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Molecular Docking | 2022 |
Administration of ciprofloxacin through a nasogastric tube in pediatric oncology and stem cell transplantation patients.
Topics: Child; Ciprofloxacin; Enteral Nutrition; Hematopoietic Stem Cell Transplantation; Humans; Intubation | 2023 |
The effects of biofilms on tumor progression in a 3D cancer-biofilm microfluidic model.
Topics: Anti-Bacterial Agents; Biofilms; Biosensing Techniques; Ciprofloxacin; Microfluidics; Neoplasms; Uro | 2021 |
Liposomes with Water as a pH-Responsive Functionality for Targeting of Acidic Tumor and Infection Sites.
Topics: Acetates; Animals; Anti-Bacterial Agents; Biofilms; Ciprofloxacin; Drug Carriers; Female; Fluorescen | 2021 |
Core-shell poly(lactide-co-ε-caprolactone)-gelatin fiber scaffolds as pH-sensitive drug delivery systems.
Topics: Animals; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Cell Line; Cell Line, Tumor; Ciprofloxa | 2018 |
Plasmid-Mediated Quinolone Resistance in Gram-Negative Pathogens Isolated from Cancer Patients in Egypt.
Topics: Anti-Bacterial Agents; beta-Lactamases; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Egypt; | 2018 |
Multiple mechanisms contributing to ciprofloxacin resistance among Gram negative bacteria causing infections to cancer patients.
Topics: Ciprofloxacin; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Genes, Bacterial; G | 2018 |
[Febrile neutropenia: is ambulatory care possible]?
Topics: Administration, Oral; Ambulatory Care; Anti-Bacterial Agents; Ciprofloxacin; Febrile Neutropenia; Hu | 2017 |
Ciprofloxacin Enhances the Chemosensitivity of Cancer Cells to ABCB1 Substrates.
Topics: ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; Ciprofloxacin; Dose-Response Relati | 2019 |
Ciprofloxacin containing Mannich base and its copper complex induce antitumor activity via different mechanism of action.
Topics: Apoptosis; Cell Cycle; Cell Proliferation; Ciprofloxacin; Copper; Drug Screening Assays, Antitumor; | 2014 |
[Modalities of management of cancer patients with febrile neutropenia in the oncology emergency unit of Gustave-Roussy and their related costs].
Topics: Adult; Aged; Ambulatory Care; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; | 2014 |
Panton-Valentine leukocidin-positive methicillin-resistant Staphylococcus aureus infections in children with cancer.
Topics: Adolescent; Anti-Bacterial Agents; Bacteremia; Bacterial Proteins; Bacterial Toxins; Child; Child, P | 2009 |
Outpatient therapy for fever and neutropenia is safe but implementation is the key.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Female; Fev | 2013 |
Longitudinal surveillance of bacteraemia in haematology and oncology patients at a UK cancer centre and the impact of ciprofloxacin use on antimicrobial resistance.
Topics: Anti-Bacterial Agents; Bacteremia; Cancer Care Facilities; Ciprofloxacin; Drug Resistance, Bacterial | 2013 |
Outpatient, sequential, parenteral-oral antibiotic therapy for lower risk febrile neutropenia in children with malignant disease: a single-center, randomized, controlled trial in Argentina.
Topics: Anti-Bacterial Agents; Argentina; Ceftriaxone; Child; Ciprofloxacin; Humans; Neoplasms; Neutropenia; | 2004 |
Differences in the proportions of fluoroquinolone-resistant Gram-negative bacteria isolated from bacteraemic children with cancer in two Italian centres.
Topics: Amikacin; Anti-Bacterial Agents; Bacteremia; Ceftazidime; Child; Ciprofloxacin; Drug Resistance, Mul | 2005 |
[Bacterial infections in cancer patients].
Topics: Administration, Oral; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Bacteria | 2005 |
Systematic reviews and meta-analysis of febrile neutropenia.
Topics: Aminoglycosides; Anti-Bacterial Agents; beta-Lactams; Ciprofloxacin; Drug Therapy, Combination; Feve | 2005 |
Ciprofloxacin treatment of acute infections in immunocompromised host.
Topics: Acute Disease; Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Clinical Tri | 1989 |
Bacteraemia in cancer patients caused by colistin-resistant Gram-negative bacilli after previous exposure to ciprofloxacin and/or colistin.
Topics: Anti-Bacterial Agents; Bacteremia; Ciprofloxacin; Colistin; Drug Resistance, Bacterial; Gram-Negativ | 2006 |
Comparison of two oral regimens for the outpatient treatment of low-risk cancer patients with chemotherapy-induced neutropenia and fever: ciprofloxacin plus cefuroxime axetil versus ciprofloxacin plus amoxicillin/clavulanate.
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Amoxicillin-Potassium Clavulanate Combination; A | 2007 |
In vitro activity of WIN 49375 compared with those of other antibiotics in isolates from cancer patients.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; Ciprofloxacin; Fluoroquinolones; Humans; Mic | 1984 |
Susceptibilities of bacterial isolates from patients with cancer to levofloxacin and other quinolones.
Topics: Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Gram-Negative Bacteria; Gram-P | 1994 |
The new fluorinated quinolones for antimicrobial prophylaxis in neutropenic cancer patients.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Drug Therapy, Combination; Gram-Negativ | 1993 |
Cutaneous and pulmonary infections caused by Mycobacterium vaccae.
Topics: Aged; Animals; Anti-Bacterial Agents; Cattle; Ciprofloxacin; Humans; Male; Middle Aged; Minocycline; | 1996 |
Hepatic dysfunction following busulfan and cyclophosphamide myeloablation: a retrospective, multicenter analysis.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bone Marrow Transplantation; Busulfan; Child; Child, | 1996 |
Prophylactic antibiotics eliminate bacteremia and allow safe outpatient management following high-dose chemotherapy and autologous stem cell rescue.
Topics: Ambulatory Care; Anti-Infective Agents; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy | 1996 |
Use of fluoroquinolones for empirical management of febrile neutropenia in pediatric cancer patients.
Topics: Administration, Oral; Anti-Infective Agents; Child; Ciprofloxacin; Fever of Unknown Origin; Humans; | 1997 |
In vitro study of the potential role of quinupristin/dalfopristin in the treatment of catheter-related staphylococcal infections.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics, Antitubercular; Bacteremia; Catheterizati | 1996 |
In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer.
Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacter | 1997 |
Fluoroquinolone prophylaxis for the prevention of bacterial infections in patients with cancer--is it justified?
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Drug Therapy; Ent | 1997 |
Infectious complications in 126 patients treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation.
Topics: Acyclovir; Adolescent; Adult; Anti-Infective Agents; Antifungal Agents; Antineoplastic Combined Chem | 1999 |
Incidence and clinical impact of fluoroquinolone-resistant Escherichia coli in the faecal flora of cancer patients treated with high dose chemotherapy and ciprofloxacin prophylaxis.
Topics: Adult; Anti-Infective Agents; Antibiotic Prophylaxis; Antineoplastic Agents; Bacteremia; Ciprofloxac | 1999 |
Feasibility of oral ciprofloxacin for the outpatient management of febrile neutropenia in selected children with cancer.
Topics: Administration, Oral; Adolescent; Adult; Ambulatory Care; Anti-Infective Agents; Blood Cell Count; C | 2000 |
Assessment and treatment of low-risk febrile neutropenic (LRFN) pediatric patients with cancer.
Topics: Anti-Infective Agents; Ceftriaxone; Cephalosporins; Child; Ciprofloxacin; Fever; Humans; Neoplasms; | 2002 |
Optimal sampling theory and population modelling: application to determination of the influence of the microgravity environment on drug distribution and elimination.
Topics: Bayes Theorem; Ceftazidime; Chromatography, High Pressure Liquid; Ciprofloxacin; Cystic Fibrosis; Fe | 1991 |
In vitro activity of cefpodoxime against bacterial isolates obtained from patients with cancer.
Topics: Bacteria; Bacterial Infections; Cefpodoxime; Ceftizoxime; Ciprofloxacin; Humans; Microbial Sensitivi | 1991 |
[Ciprofloxacin in the treatment of infections in oncology patients].
Topics: Administration, Oral; Bacteria, Aerobic; Bacterial Infections; Ciprofloxacin; Drug Resistance, Micro | 1990 |
In vitro activity of sparfloxacin (CI-978; AT-4140) against clinical isolates from cancer patients.
Topics: Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Fleroxacin; Fluoroquinolones; | 1990 |
In vitro activity of PD127,391, a new quinolone against bacterial isolates from cancer patients.
Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacter | 1990 |
In-vitro activity of PD 117 596, a new quinolone, against bacterial isolates from cancer patients.
Topics: Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Fluoroquinolones; Gram-Negativ | 1990 |
[Peroral ciprofloxacin in the therapy of infections in oncology patients].
Topics: Adolescent; Adult; Aged; Bacterial Infections; Ciprofloxacin; Female; Humans; Immune Tolerance; Male | 1990 |
Oral ciprofloxacin therapy for infections in cancer patients.
Topics: Adult; Aged; Bacterial Infections; Ciprofloxacin; Female; Humans; Male; Microbial Sensitivity Tests; | 1989 |
Intravenous ciprofloxacin for infections in cancer patients.
Topics: Bacterial Infections; Ciprofloxacin; Drug Therapy, Combination; Female; Humans; Infusions, Intraveno | 1989 |
Treatment of sepsis in patients with neoplastic diseases with intravenous ciprofloxacin.
Topics: Adult; Aged; Ciprofloxacin; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Male; | 1989 |
Survey of antibiotic susceptibility among gram-negative bacilli at a cancer hospital.
Topics: Anti-Bacterial Agents; Aztreonam; Cefoperazone; Ceftazidime; Ciprofloxacin; Gram-Negative Bacteria; | 1988 |
Treatment of infections in non-neutropenic patients with cancer, AIDS, or renal transplant using ciprofloxacin.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Aged, 80 and over; Bacterial Infections; Ciprofloxa | 1988 |
In-vitro activity of Sch 34343, a new penam, against gram-positive isolates from cancer patients.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Fluoroquinolones; | 1986 |
Comparative in vitro activity of the new difluoro-quinolone temafloxacin (A-62254) against bacterial isolates from cancer patients.
Topics: Anti-Infective Agents; Bacteria; Ciprofloxacin; Enterobacteriaceae; Fluoroquinolones; Humans; Microb | 1988 |
In vitro activity of fleroxacin (Ro23-6240), a new fluorinated 4-quinolone against isolates from cancer patients.
Topics: Anti-Infective Agents; Ciprofloxacin; Enoxacin; Fleroxacin; Fluoroquinolones; Gram-Negative Bacteria | 1988 |
Chemoprophylaxis of bacterial infections in granulocytopenic patients with ciprofloxacin.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Antineoplastic Agents; Bacterial Infections; Ciprof | 1987 |
In vitro evaluation of difloxacin (A-56619), A-56620, and other 4-quinolones against isolates from cancer patients.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Evaluation, Preclinical; Fluoroquinolones; Gram-Negative | 1987 |
In-vitro activity of cefpirome (HR-810), WIN-49375, BMY-28142 and other antibiotics against nosocomially important isolates from cancer patients.
Topics: Anti-Bacterial Agents; Cefepime; Cefpirome; Cephalosporins; Ciprofloxacin; Cross Infection; Fluoroqu | 1986 |
In vitro evaluation of S-25930 and S-25932, two new quinolones, against aerobic gram-negative isolates from cancer patients.
Topics: Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Enoxacin; Fluoroquinolones; Gram-Negativ | 1987 |